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The loss of dopaminergic neurons (DAn) and reduced dopamine (DA) production underlies the
reasoning behind the gold standard treatment for Parkinson’s disease (PD) using levodopa (L-DOPA).
Recently licensed by the European Medicine Agency (EMA) and US Food and Drug Administration (FDA),
safinamide [a monoamine oxidase B (MOA-B) inhibitor] is an alternative to L-DOPA; as we discuss here,
it enhances dopaminergic transmission with decreased secondary effects compared with L-DOPA. In
addition, nondopaminergic actions (neuroprotective effects) have been reported, with safinamide
inhibiting glutamate release and sodium/calcium channels, reducing the excitotoxic input to
dopaminergic neuronal death. Effects of safinamide have been correlated with the amelioration of non-
motor symptoms (NMS), although these remain under discussion. Overall, safinamide can be considered
to have potential antidyskinetic and neuroprotective effects and future trials and/or studies should be
performed to provide further evidence for its potential as an anti-PD drug.Introduction
PD is the second most-common chronic neurodegenerative disor-
der worldwide, characterized by the degeneration of DAn and
deficient DA production in the nigrostriatal pathway [1,2]. Clini-
cally, it is recognized by a core of motor symptoms, including
bradykinesia, rigidity, tremor, and postural instability, which are
used to establish its diagnosis [3]. Although it has been postulated
that PD itself is not a primary cause of death, studies have proposed
that death might occur as a secondary result of the progression of
PD motor dysfunctions, for example, as a result of falls in patients
with advanced-stage PD [4–6]. In addition, the development of
NMS, such as sleep disturbances, depression, olfactory dysfunc-
tion, and behavioral and/or cognitive problems, has also been
linked with functional disabilities [7–10]. Therefore, managementPlease cite this article in press as: Teixeira, F.G. et al. Safinamide: a new hope for Parkinson
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https://doi.org/10.1016/j.drudis.2018.01.033 strategies have been preferred, involving the diagnosis and evalu-
ation of the condition of the patient, followed by the development
and application of personalized strategies, aiming to ameliorate
the patient’s quality of life [11–13]. Still, as recently reviewed by
Onofrj and colleagues [14], satisfactory approaches to relieve
the symptoms, or slow down the progression, of PD by protecting
DAn from premature death remain lacking. Promising results have
been experimentally and clinically obtained with several drugs,
yet the challenge remains to show a clinical proof of arrest of delay
of DAn loss in PD.
The current symptomatic treatment relies on the use of phar-
macological strategies, such as L-DOPA, which remains the gold
standard treatment, DA agonists (DAAs; e.g., ropinirole or prami-
pexole), and MAO-B (e.g., rasagiline or selegiline) and catechol-O-
methyltransferase (COMT; e.g., entacapone or tolcapone) inhibi-
tors, to compensate for the deficits of DA in the nigrostriatal
dopaminergic pathway [15–17] (Fig. 1). Although efficacious, they’s disease?, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.01.033
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FIGURE 1
Current Parkinson’s disease (PD) treatments. Considering PD as a single diagnostic entity because of the (a) loss of dopamine (DA) was and has been effective in
the development and application of (the available) (b) symptomatic treatments (e.g., DA level re-establishment), but insufficient to stop PD progression through
neuroprotective or disease-modifying actions. Abbreviations: COMTis, catechol-O-methyltransferase inhibitors; DAn, dopaminergic neuron; L-DOPA, levodopa;
MAO-Bis, monoamine oxidase B inhibitors; TH, tyrosine hydroxylase.
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long periods of time [14]. In addition, although surgical interven-
tions, such as deep brain stimulation (DBS), have also been used as
strategies for the treatment of PD, the apparent clinical recovery is
not effective in the long-term and the progression of the disease is
not halted [18]. Molecular agents (e.g., mGluR4 agonists; CEP-
1347; GM1 ganglioside, CoQ10, and NAC) and gene engineering
approaches [e.g., induction of glutamic acid decarboxylase (GAD)
enzyme in the striatum; delivery of synthetic enzymes to increase
striatal DA levels, and local infusion of neurotrophic factors to
protect and restore nigral DA neurons] have also been developed
and used in the treatment of PD [19–26]. However, none of the
currently available strategies delay or halt its progression. The
main reason for the failure of these approaches could be partly
explained by the simplistic view and/or targeting and inadequate
definition of PD [27]. In fact, in addition to DAn degeneration and
DA depletion, multiple factors, including oxidative stress, mito-
chondrial dysfunction, excitotoxicity, and inflammation, have
also been described as being involved in the initiation and pro-
gression of PD. This makes PD a multitargeted disease in which
drugs, with a multimodal action, could be of particular value [28].
Thus, safinamide was recently proposed as a promising new mul-
timodal PD drug [29]. Here, we discuss the current understanding
of safinamide, addressing its therapeutical potential in preclinical
and/or clinical applications, ongoing clinical trials and future
prospects.
Safinamide
(S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]aminopropa-
namide methanesulfonate, safinamide, is a new molecule ap-
proved by the European Economic Area (EEA), EMA, and FDA
as ‘an add-on therapy to stable dose L-DOPA, alone or in combi-
nation with other PD therapies in mid-to late-stage-fluctuating
PD patients’ [30]. Safinamide has been described as a multimodal
drug, combining dopaminergic and nondopaminergic actions,
although it remains unclear how the nondopaminergic proper-
ties contribute to its global effect [31,32]. Whereas the dopami-
nergic action of safinamide leads to increased DA levels in thePlease cite this article in press as: Teixeira, F.G. et al. Safinamide: a new hope for Parkinson
2 www.drugdiscoverytoday.combrain through its highly selective and reversible inhibition of
MAO-B, its nondopaminergic actions have been correlated with
the blocking of voltage-gated sodium channels and modulation
of N-type calcium channels, with the consequent inhibition of
excessive glutamate release [30,33]. In addition, although safi-
namide has been correlated with a linear pharmacokinetic after
single or repeated administrations (suggesting that it is involved
in enzyme inhibition or induction), the capacities of the ami-
dases involved in its metabolism have not yet been fully charac-
terized [30].
Safinamide at doses of 50–200 mg/day are safe and well tolerated,
with low incidences of AEs compared with placebo [30]. Moreover,
it shares a comparable efficacy with entacapone in reducing
motor fluctuations, but with greater tolerability, including reduced
nausea, vomiting, shortness of breath, urine abnormalities, and
dizziness [34]. However, the concomitant consumption of safina-
mide has been associated with: (i) increased risk of fractures and falls
when used with anxiolytics and antihypertensive drugs; (ii) in-
creased risk of psychoses with amantadine use; and (iii) increased
risk of neuropsychiatric AEs in patients taking DAAs [30]. The
potential interactions of safinamide with amantadine and selective
serotonin reuptake inhibitors (SSRIs) could also pose some limita-
tions in clinical practice, especially in late stages of PD, given
that serious AEs have been reported for other MAO-B inhibitors
when used in combination with SSRIs and other antidepressants.
These doubts could be mitigated by growing clinical practice and
during postmarketing surveillance.
Thus, although safinamide differs from the currently MAO-B
inhibitors rasagiline and selegiline because of its reversible mode
of MAO-B inhibition, the clinical relevance of this difference is
still not fully understood [30,32,35]. The reversible mode of
safinamide represents an advantage, because studies have sug-
gested that unspecific inhibition of MAO leads to unmetabolized
dietary amines entering the circulatory system, where they in-
duce noradrenaline release from peripheral adrenergic neurons,
leading (in most cases) to a severe and potentially fatal hyperten-
sive response. Therefore, to avoid such effects, MAO-B inhibitors
with high selectivity, such as safinamide, are crucial for the’s disease?, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.01.033
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safinamide exhibits potent, highly selective, and reversible
MAO-B inhibition (with full inhibition in human platelets at
0.6 mg/kg orally) [35,37], with its selectivity for MAO-B being
relatively superior to that of selegiline and rasagiline, thus de-
creasing the need for dietary restrictions, such as the ‘cheese
effect’ [30,37]. Binding studies in rat brain mitochondria (in vitro)
demonstrated that safinamide has 5000 times greater selectivity
for MAO-B (and 1000-fold selectivity over MAO-A in rat and
human brains, respectively [30,35,38]) compared with 127 times
and 103 times greater selectivity for MAO-B over MAO-A with
selegiline and rasagiline, respectively [30,36,39]. Interestingly, in
addition to such greater selectivity, MAO-B inhibition by safina-
mide is also fully reversible, because it does not form irreversible
covalent bonds with MAO-B, in comparison with selegiline and
rasagiline [31,40,41]. This is an important advantage for patients
who experience AEs that need to be treated with other drugs,
because the reversibility of safinamide avoids potential drug
interactions [42–45]. From the (dosage) administration point of
view, safinamide is water soluble and rapidly absorbed; by using a
single oral dose of 100 mg safinamide, a maximum plasma con-
centration was found after approximately 2 h, being approxi-
mately 650 ng/ml and the area under the curve (AUC) being
19 000 ng/ml h [30]. In addition, although several studies have
documented a secondary peak approximately 45 min after the
first peak, safinamide has an elimination half-life of 21–24 h,
allowing once-daily administration, with food intake not found
to affect its absorption or bioavailability [33]. Indeed, as demon-
strated by studies in animal models, brain levels of safinamide
were higher than the corresponding plasma concentrations,
demonstrating that the drug is largely biotransformed, also sup-
ported by the very low dosage of unchanged safinamide found in
urine and feces; its plasma protein binding is 92%, and only a
small proportion is excreted unchanged [33]. This could be rele-
vant for patients with PD, because its effect quickly disappears,
unlike selegiline or rasagiline, whose actions take several weeks to
washout [30,31,46]. In addition, although studies with animal
models have provided neuroprotective and neurorescuing prop-
erties of safinamide (which might result from its nondopaminer-
gic actions), no evidence from human studies have confirmed
these neuroprotective effects [29,37]. Thus, definitive conclu-
sions on the efficacy and tolerability of safinamide compared
with other PD drugs (e.g., selegiline, rasagiline, entacapone, or
amantadine) are not yet possible, highlighting the need for
additional research to fully elucidate the potential (neuroprotec-
tive) effect of safinamide in patients with PD [29].
Preclinical evidence for the efficacy of safinamide in
PD
Espay and colleagues [27] assumed that approaching PD as a single
diagnostic entity (e.g., dopamine-dependent disease) would be
effective in the development of symptomatic therapies, but
notably ineffective when targeting neuroprotection or attempting
disease-modifying strategies. Such inefficacy might be explained
in part by the simplistic single-target approach that has been
established for drug development [27]. Nevertheless, the MAO-B
inhibitors selegiline and rasagiline have been described as being
able to mitigate PD progression [47,48]. Still, their neuroprotectivePlease cite this article in press as: Teixeira, F.G. et al. Safinamide: a new hope for Parkinsonaction potential has been surrounded by controversy [49–52].
While for selegiline, studies have yet to reach a definitive conclu-
sion [53,54], the use of rasagiline in preclinical and/or clinical
studies demonstrated a delayed and reduced need for the future
use of L-DOPA [55–57]. However, there are still difficulties in
documenting disease-modifying and/or neuroprotective effects
when considering a PD drug with a symptomatic benefit [57].
Therefore, safinamide has been suggested to demonstrate efficacy
as a multitargeted PD drug [32,58].
Preclinical models of PD have demonstrated that, in addition to
the symptomatic benefits of safinamide in PD resulting from the
increase in DA levels through MAO-B inhibition, its nondopami-
nergic actions, including the attenuation of sodium/calcium chan-
nels and glutamate release, could lead to neuroprotective effects
[37] (Fig. 2). In addition, neurorescuing and tremorolytic charac-
teristics were also observed in PD animal models [59], as well as a
reduction in the duration and intensity of L-DOPA-induced dys-
kinesia in parkinsonian nonhuman primates [60]. More recently,
anti-inflammatory properties of safinamide have also been evi-
denced, with a role in blocking sodium channels in the activation
of microglia, thereby suggesting that safinamide could reduce
microglial activation and inflammation [28,61]. It has also been
shown that safinamide enhances the development of a phagocytic
phenotype in microglia in vitro, by improving the expression of
arginase-1, a feature of a neuroprotective microglial phenotype
known as ‘M20 [28]. Notably, the changes in microglial phenotypes
depend on the disease stage and severity. Therefore, as recently
reviewed by Tang and Le [62], mastering the stage-specific switch-
ing of M1/M2 phenotypes within appropriate time windows
could provide better therapeutic benefit for PD. Thus, the suppres-
sion of microglial activation together with the other nondopami-
nergic activities of safinamide (Fig. 2) could be clinically relevant,
although more studies should be performed to address such
hypotheses.
Clinical evidence for the efficacy of safinamide in PD
Most treatment strategies for PD act by increasing dopaminergic
activity. L-DOPA remains the most-effective therapeutic ap-
proach and the gold standard treatment in PD [63]. Other thera-
pies, such as COMT and MAO-B inhibitors, are used as add-on
therapies to L-DOPA to increase the level of its unmetabolized
form [63]. Until later stages of the disease, this strategy is effective
in improving the motor symptoms and, therefore, treating the
wearing-off phenomena, until later stages of the disease. Howev-
er, long-term treatment with L-DOPA leads to troublesome motor
fluctuations and/or L-DOPA-induced motor complications (MC;
e.g., dyskinesias) [64]. In addition, the presence of NMS also
causes significant clinical impairments, with the added difficulty
of presenting a nonlinear clinical progression [2]. Thus, both
dopaminergic and nondopaminergic strategies have to be tackled
and combined during the course of the disease, a scenario in
which safinamide is a promising choice [37]. Currently, 37 trials
have been conducted on safinamide use, comprising 20 Phase I
trials, nine Phase II trials, and eight Phase III trials [30]. Here,
we provide a critical summary of some of these studies, paying
particular attention to their inclusion criteria, design, and out-
comes, and addressing outstanding questions that call for further
studies.’s disease?, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.01.033
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FIGURE 2
The multimodal profile of safinamide. (a) The reversible inhibition profile of monoamine oxidase B (MAO-B) by safinamide either alone or as an add-on to
levodopa (L-DOPA) has been correlated with improvements in Parkinson’s disease (PD) symptoms, increasing dopaminergic neuronal transmission
because of the consequent increase in dopamine availability. In contrast to the majority of available PD drugs, (b) neuroprotective and disease-modifying
effects of safinamide have also been claimed because of its capacity to block voltage-dependent sodium and N-type calcium channels, therefore
inhibiting glutamate release. In addition, the modulation and/or suppression of microglial activation has also been linked to safinamide effects,
suggesting an anti-inflammatory profile, which could be clinically important, given that microglia are implicated dopaminergic neuronal loss.
Abbreviation: TH, tyrosine hydroxylase.
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To the best of our knowledge, there is only one study in ‘de novo’
(drug-naı¨ve) ‘early-stage’ PD (Hoehn and Yahr Scale (HY) stage I or
II; Study 009) [65]. In this Phase II study, safinamide (median dose
of 70 mg/day; range: 40–90 mg/day) provided a reduction of at
least 30% in the UPDRS-III score (only significant in the higher
dose group) compared with 21.4% of placebo patients. However,
this study had a follow-up period of only 3 months (12 weeks), and
the dose of safinamide was, on average, low and adjusted to the
body weight (0.5 or 1 mg/kg), instead of a fixed 50/100/200 mg
dosage.
Intermediate stages of PD, without motor complications
In intermediate stages of PD (patients with HY stage I–III with a
disease duration of less than 5 years and already treated by DAAs
but without L-DOPA-induced MCs), three Phase III studies have
been published: Study 015 [66], Study 017 [67], and MOTION
study [68]. These studies only screened patients with PD taking
DAAs and, as such, patients taking L-DOPA have not yet been
investigated.
In the Study 015, which was a 12-month double-blind study,
patients with PD received a stable dose of a single DAA, and were
then randomized to one daily dose of 100 or 200 mg of safina-
mide, or a placebo. The group receiving 100 mg of safinamide
showed the most-significant improvements in their UPDRS III
score (3.90 for 200 mg, 6.0 for 100 mg, and 3.60 for placebo),
Clinical Global Impression Change from baseline (CGI-C; +0.98
for 200 mg, +3.1 for 100 mg, and 3.4 for the placebo group), andPlease cite this article in press as: Teixeira, F.G. et al. Safinamide: a new hope for Parkinson
4 www.drugdiscoverytoday.comactivities of daily life (UPDRS-II; 1.4 for 200 mg, 2.2 for
100 mg, and 1.2 for the placebo group). However, a higher dose
of 200 mg of safinamide did not demonstrate any significant
improvement.
Study 017 [67], a 12-month, randomized, double-blinded, pla-
cebo-controlled study of 227 patients with PD, was an extension of
Study 015. The primary efficacy endpoint was the time from
baseline (Study 015 randomization) to ‘intervention’, defined
as: increase in DAA dose; addition of another DAA, L-DOPA, or
other PD treatment; or discontinuation because of a lack of effica-
cy. From the pooled data, and in terms of the safinamide-treated
groups, the primary endpoint failed to reach statistical signifi-
cance. Yet, post-hoc analyses revealed that patients receiving
100 mg/day of safinamide experienced a significantly lower rate
of intervention (25% versus 51%, respectively) and a delay in
median time to intervention of 9 days (240–540-day analysis)
compared with placebo.
Finally, the MOTION study [68], a Phase III, 24-week, double-
blind placebo-controlled trial of 679 patients with PD, explored
the efficacy and safety of doses of 50 and 100 mg/day of safinamide
as an add-on therapy to a single stable DAA. The results showed
that 100 mg/day significantly improved PD motor symptoms
(UPDRS III) and activities of daily living.
Advanced-stage of PD with motor complications
In patients with advanced-stage PD and L-DOPA-induced MC,
three randomized, double-blind, placebo-controlled studies have
examined the efficacy of safinamide: Study 016 [69], Study 018’s disease?, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.01.033
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trial NCT00627640 [72].
In Study 016, 669 patients with PD (with an off-duration greater
than 1.5 h/day) were randomized to either doses of 50 or 100 mg/
day of safinamide, or placebo for 3 months [69]. The addition
of safinamide to L-DOPA significantly increased total on-time
with no or nontroublesome dyskinesia (1.36  2.63 h and
1.37  2.75 h, respectively, compared with 0.97  2.38 h observed
in placebo group). In addition, a decreased off time and improved
motor symptoms (UPDRS-III) and Clinical Global Impression-
Change (CGI-C) were also observed [69].
In Study 018, 554 patients with PD who had completed Study
016 were enrolled and randomized to doses of 50 or 100 mg/day of
safinamide or to a placebo over a period of 6 and 18 months, with a
total of 2 years of follow-up [70]. The primary endpoint of this
study was set as the change in Dyskinesia Rating Scale (DRS) total
score during on-time over 6 months. Although the safinamide
groups presented a decrease in the mean of the total DRS score,
significant differences were not observed compared with the pla-
cebo group. Study 018 further supported findings already evident
from Study 016, showing significant clinical benefits (e.g., on-time
without troublesome dyskinesia, off-time, activities of daily living,
motor symptoms, quality of life, and symptoms of depression),
which were found to be improved at 6 months and remained
significant even after 2 years of follow-up.
In the SETTLE study [71], 549 patients with advanced PD were
randomized for placebo or 50–100 mg safinamide as an add-on
therapy to a stable dose of L-DOPA, for 6 months. As in Study
016, improvements were observed in the mean on-time with no
or nontroublesome dyskinesia. Notably, a greater proportion of
patients treated with safinamide 50–100 mg had an improve-
ment in both on- and off-time (either when considering the 30-
min or 60-min cut off in both on- and off-time and a 20%
or 30% improvement in the UPDRS III scores, respectively).
Interestingly, the same clinical benefits were shown in Study 016
and Study 018, reinforcing the effects of safinamide on improv-
ing motor symptoms, CGI-C, Patient’s Global Impression of
Change, activities of daily living and health-related quality of
life (Parkinson’s Disease Questionnaire-39 and EuroQol-5
Dimensions). However, as in Study 018, the severity of dyski-
nesias (DRS score) did not improve. In addition, most of the
patients included in Study 018 had at baseline predominantly
lower scores of DRS, suggested that there was not an overexpres-
sion of patients with the phenotype of motor fluctuations pre-
dominantly of off-time. A post-hoc analysis of Study 016 and the
SETLLE study confirmed the efficacy of safinamide in reducing
the off-time compared with placebo [73]. Nonetheless, post-hoc
analysis of study 018, stratifying patients on the presence/
absence of dyskinesia at baseline or changes in L-DOPA dose
during the study, showed that safinamide 100 mg improved the
DRS score (p = 0.0488), but only among patients who did not
change their L-DOPA dose [73].
In a more-recent double-blind, 6-month Phase III trial,
NCT00627640 [72], safinamide (50–100 mg/day) was used as
an add-on versus placebo in patients taking stable dosages of
L-DOPA and concomitant PD medication. The study had the
same inclusion criteria and outcomes as Study 016 and the
SETTLE study, in which the researchers were instructed to in-Please cite this article in press as: Teixeira, F.G. et al. Safinamide: a new hope for Parkinsoncrease the dose of safinamide up to 100 mg/day, after day 14.
This study showed once again that safinamide was significantly
effective in reducing off-time without troublesome dyskinesias.
Yet, as in Study 018 and SETTLE, dyskinesia was still frequently
reported as an AE [in 40 (14.6%) versus 15 (5.5%)] and as a severe
AE [in 5 (1.8%) versus 1 (0.4%)]. Thus, although the dose of
100 mg/day provides the most-significant motor benefits, this
might be at the expense of increased incidence of dyskinesias, at
least in some patients. However, in line with the study design, the
researchers were not allowed to reduce the dose of L-DOPA,
raising the question of whether this would have reduced the
incidence of dyskinesias.
In summary, there is clinical evidence to support that safina-
mide, mostly with an optimal dose of 100 mg/day, can be effective
in improving motor symptoms (reducing UPDRS III score) when
used alone in early, untreated PD [65]. In intermediate-stage of PD
[71,73], and also favoring 100 mg/day, there is strong evidence
that safinamide, when used as an add-on therapy to a single DAA,
leads to improvements in motor symptoms [68]. In advanced-stage
PD with motor fluctuations, the addition of safinamide 50 mg/day
or 100 mg/day to L-DOPA, as well as providing a symptomatic
effect (reducing off-time and decreasing motor symptoms) [69,70],
is also effective in significantly increasing the total on-time with
no or nontroublesome dyskinesia [58]. Furthermore, although
supported in ad hoc subgroup analysis [70], safinamide might
reduce the severity of dyskinesias in patients who already have
moderate–severe dyskinesias over the long term (2 years of follow-
up). There is no evidence that safinamide precludes the appear-
ance of dyskinesias compared with L-DOPA. However, higher
doses of safinamide (100 mg/day) might aggravate the severity
of dyskinesias. Moreover, robust evidence remains lacking for
whether safinamide is able to delay the time to intervention
[67], negating the need for L-DOPA.
PD non-motor symptoms
NMS, such as cognitive impairment and depression, are now
recognized to be integral to PD during the prodromal phase and
throughout the course of the disease, being a major contributor to
the worsening of patient outcomes and quality of life [74,75].
Yet, there is still a paucity of effective therapies for NMS and the
efforts of research in this field are lagging behind research
on motor symptoms and complications. Currently, the only
approved symptomatic drug for dementia in PD is rivastigmine,
a cholinesterase inhibitor [76]. Although its symptomatic effect in
dementia in PD and long-term safety have been established, there
is no clear evidence for its use in mild cognitive impairment in PD
(PD-MCI), or for its ability to halt disease progression [77]. There-
fore, there are upcoming novel compounds expanding to the
cognition field, with drugs targeting the glutamatergic, dopami-
nergic, noradrenergic, and serotonin systems [75]. In a trial using
rasagiline, an improvement of patient-rated cognitive and depres-
sion outcomes was observed in patients with PD-MCI, highlight-
ing the potential of this treatment [78]. However, subsequent trials
of rasagiline, using neuropsychological assessment outcomes,
failed to prove a meaningful benefit in cognition or depression
[79]. The results of a multicenter Phase II (NCT01211587) double-
blind clinical trial using safinamide 100 mg/day controlled
with placebo in patients without dementia but with cognitive’s disease?, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.01.033
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mide on cognition in PD.
In terms of PD-related depression, there are currently several
clinical trials reinforcing its role in PD and, in contrast to other
causes of depression, this could be the result of the larger range of
dopaminergic deficits involved in PD. In fact, when dopamine
agonists, such as rotigotine in the RECOVER study [80] and
apomorphine [81], were applied, significant improvements in
depression scores on the Beck Depression Inventory (BDI) and
NMS scores were observed. Also with rasagiline, a post-hoc analysis
revealed significantly less worsening of depression scores on the
MDS-UPDRS experiences of daily living, compared with placebo
after 36 weeks of follow-up in the ADAGIO study [78]. Notably, as
recently reviewed by Finberg and Rabey [41], despite the strong
antidepressant efficacy of irreversible MAO inhibitors, their clini-
cal use has been limited because of their AEs in potentiating
cardiovascular effects of dietary amines. Thus, the use of reversible
MAO-B inhibitors, such as safinamide, have demonstrated a safer
profile, thereby justifying further studies in PD with cognitive and/
or depression impairment.
Concluding remarks
Disease-modifying and/or neuroprotection effects are the Holy
Grail for PD treatment, which, up to now, all antiparkinsonian
drugs have failed to demonstrate. A disease-modifying effect
reflects an intervention that modifies the natural clinical course
of PD. Hopes were prematurely raised by the DATATOP trial
[selegiline and selegeline + tocophenol (vitamin E) in patients
with drug-naı¨ve PD] [82], ADAGIO study (rasagiline in patients
with drug-naı¨ve PD) [83], SINDEPAR study [sinemet(levodopa/
carbidopa)-Deprenyl(selegeline)-Parlodel(bromocriptine)] [84], as
well as by the SELEDO study (selegiline combined with L-DOPA in
earlier stages of PD) [85], which all claimed to show that a proven
delay in the need to start L-DOPA treatment resulted from a
disease-modifying effect of the drugs involved. However, all these
studies are plagued by the same issue, that these drugs (selegiline,
rasagiline, and bromocriptine) have prodopaminergic effects.
Thus, it is impossible to separate the confounding symptomatic
benefits, which can have a carry-over motor effect over weeks to
months, from any disease-modifying effects. Using neuroimaging
outcomes with 123I-b-CIT SPECT in the CALM-PD study (prami-
pexole) [86], the authors suggested that this drug slowed the loss of
DA-imaging markers relative to standard L-DOPA. Yet, these
changes can be better interpreted in terms of drug-related DA
regulation than a real structural neuroprotection, as shown in
the PROUD-PD study [87]. Thus, we expect that, if one only takes
into account its MAO-B inhibition effect, safinamide will have the
same difficulties as all previous drugs in having a disease-modify-
ing effect in PD. Nevertheless, these difficulties should not pre-
clude further studies, especially in intermediate-stages of PD,
before the development of motor fluctuations, to reinforce the
hypothesis that safinamide, when used as an add-on therapy to L-
DOPA, is able to reduce its daily dosage, and eventually delay the
incidence of MCs [35,88]. Also, in advanced stages of PD, with
dyskinesias, future trials, or even ongoing clinical experiments,
should determine whether the strategy of adding safinamide and
lowering L-DOPA dosages will lead to a reduction in severe dyski-
nesias while simultaneously delivering the same motor benefits.Please cite this article in press as: Teixeira, F.G. et al. Safinamide: a new hope for Parkinson
6 www.drugdiscoverytoday.comIn terms of the MAO-B inhibition properties of safinamide, there
are no studies comparing safinamide with rasagiline, selegiline, or
entacapone; given the results from the LARGO study (rasagiline
versus entacapone added to L-DOPA scheme) [89], we expect that
the increased on-time without troublesome dyskinesias is in fact
similar across the three drugs.
In contrast to disease-modifying effects, neuroprotection
implies the protection of neurons from death or dysfunction
resulting from the ongoing neuropathological processes; this is
one of the unmet needs for PD, because current therapies do not
address its degenerative progress [37]. Based on preclinical studies,
safinamide has been shown to have neuroprotective and anti-
inflammatory effects in both in vitro and in vivo animals models
of PD [37], although human data are still missing. The pleomor-
phic pharmacological properties of safinamide, especially its non-
dopaminergic properties (e.g., inhibition of voltage-dependent
sodium channels and inhibition of stimulated glutamate) raise
some hope for potential neuroprotective and disease-modifying
effects on PD [28,31].
In terms of NMS, further evidence is also needed to corroborate
the potential benefit of safinamide on depression, as was suggested
by the results of Study 18 [70], as well as on cognition, as suggested
by the results of NCT01211587.
Magnetic resonance imaging (MRI) studies of the brain, in
particular through functional MRI (fMRI), might be one of the
best strategies to address several of these open questions. Func-
tional MRI would allow one to explore the role of safinamide as a
disease-modifying agent of motor and NMS of PD, especially its
cognitive deficits and depressive symptoms, and to specify the
neuronal circuits modulated by the drugs. We hypothesize that
safinamide could enhance the effect of L-DOPA by acting through
both dopaminergic and glutamatergic pathways. Therefore,
patients with PD under concomitant safinamide treatment could
show a different recruitment of limbic- and cognition-related
brain circuits, which could be assessed through both resting-state
(rs) and task-related fMRI in addition to the described effects of L-
DOPA in motor areas (Fig. 3). Notably, rs-fMRI has been shown to
reveal functional reorganizations in PD through different
approaches, both in patients with PD under dopamine-replace-
ment therapies (DRT) and drug-naı¨ve PD [90]. Particularly,
patients with PD appear to present reduced corticostriatal func-
tional connectivity and L-DOPA appears to partially normalize
these functional connectivity imbalances. Thus, further connec-
tomic analyses are needed to assess whether: (i) treatment with
safinamide alone, or in combination with L-DOPA, has the ability
to improve even further the normalization of these functional
connectivity imbalances, to the same extent as L-DOPA (itself);
and (ii) the improvements are associated with changes in network
topology; and (iii) what other networks, besides the dopaminergic
pathways, are involved.
Thus, satisfactory approaches to relieve the symptoms, or to
slow down the progression, of PD by protecting DAn from
premature death remain missing. Although promising results
have been experimentally and clinically obtained with several
drugs, the challenge is still to show a clinical proof of arrest or
delay of DAn loss in PD [14]. In addition to DAn degeneration and
DA depletion, multiple factors, including oxidative stress, mito-
chondrial dysfunction, excitotoxicity, and inflammation, have’s disease?, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.01.033
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FIGURE 3
Hypothesized brain areas modulated by safinamide. The dopaminergic action of safinamide appears to have an impact in (particularly) motor areas, similarly to
the effects of levodopa (L-DOPA), thus reducing motor symptoms (a). Additionally, its nondopaminergic action might contribute to the reduction in non-motor
symptoms, namely improving depressive symptoms by modulating the limbic system (b) or reducing cognitive impairment by modulating nondopaminergic
circuits important for different cognitive functions (c).
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sion of PD [91]. This makes PD a multitargeted disease in which
new strategies, with a multimodal action, could be of particular
value [31,44,92]. Such a profile has been linked to safinamide,
based on its high selective and reversible inhibition of MAO-B,
leading to an increase in available DA (dopaminergic action of
safinamide). In addition to dopaminergic transmission, safina-
mide has also been linked with nondopaminergic actions (e.g.,
neuroprotective and/or disease-modifying strategies [14,28]),
blocking sodium channels and modulating the function of calci-
um channels, thereby inhibiting the release of glutamate [93].
Such properties show more potential compared with those of
selegiline and rasagiline effects, although it is advised that all of
the above-referred compounds should be taken daily. However,
in the case of selegiline and rasagiline, there questionable results
remain, because both drugs inhibit MAO-B in an irreversible
manner [94]. In addition, it has been also claimed that a selegiline
and rasagiline daily regimen might also cause inhibition of MAO-
A, although this awaits investigation in patients with PD. With
safinamide, although more studies are needed to fully understood
all its modes of action, several clinical trials have demonstrated
its efficacy and tolerability, suggesting an optimal dosage raging
from 50 to 100 mg/day, correlated with an improvement in on-
time and reduction in off-time. If a preventive strategy of motorPlease cite this article in press as: Teixeira, F.G. et al. Safinamide: a new hope for Parkinsoncomplications with safinamide is possible, as defended by Thom-
as Mu¨ller [32,95], this will open the way for the wider use of
safinamide for the prevention and treatment of motor complica-
tions. However, it will be necessary to investigate in more detail
the impact of safinamide on L-DOPA pharmacokinetics with and
without COMT inhibition in view of increasing L-DOPA levels
during safinamide treatment. In addition to its effects on motor
complications, safinamide might also have putative cognition-
enhancing effects (although this needs to be proven) [14,95],
making it an essential future PD drug, capable of modulating
altered dopaminergic and glutamatergic neurotransmission in
patients with PD. Therefore, future clinical trials and/or studies,
especially with longer follow-up times, either in patients with de
novo drug-naı¨ve PD or with intermediate stages of PD (without
MCs and/or cognitive impairment), could provide further en-
lightenment on these outstanding questions.
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